Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment

Melvin E Andersen1, David C Dorman, Harvey J Clewell

  • 1The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709-2137, USA.

Insights

Physiologically based pharmacokinetic (PBPK) models for manganese (Mn) have been developed using new animal data. These models simulate Mn tissue kinetics and aid in risk assessment for human overexposure.

Area of Science:

  • Environmental toxicology
  • Pharmacokinetics
  • Risk assessment

Background:

  • Manganese (Mn) is essential but toxic at high levels.
  • Previous work proposed a methodology for Mn tissue-dose risk assessment.
  • Significant new pharmacokinetic (PK) data in animal models has since been generated.

Purpose of the Study:

  • To review the development of Mn physiologically based pharmacokinetic (PBPK) models.
  • To reassess data requirements for Mn risk assessment.
  • To detail the application of PBPK models in Mn risk assessment.

Main Methods:

  • Development of PBPK models for Mn using extensive animal PK data.
  • Incorporation of homeostatic control, saturable binding, and tissue-specific fluxes.
  • Simulation of Mn tissue kinetics from both inhalation and oral intake.

Main Results:

  • PBPK models effectively simulate Mn tissue kinetics in rodents and nonhuman primates.
  • Models capture dose-dependent Mn disposition characteristics.
  • Minor data gaps remain, but models provide a framework for human PK description.

Conclusions:

  • Developed Mn PBPK models are valuable tools for risk assessment.
  • Models integrate ingestion and inhalation kinetics with Mn homeostatic control.
  • These PBPK models advance the goal of tissue-dose based risk assessment for Mn.

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Multicompartment Models: Overview01:14

Multicompartment Models: Overview

Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...